Literature DB >> 16015705

Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis.

Shi-Min Luo1, Wei-Min Tan, Wei-Xiong Deng, Si-Min Zhuang, Jian-Wei Luo.   

Abstract

AIM: To explore the expression of albumin (ALB), insulin-like growth factor (IGF)-1, and insulin-like growth factor binding protein (IGFBP)-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma (HCC) patients with cirrhosis.
METHODS: Twenty-four HCC patients with cirrhosis who underwent hepatectomy were studied. ALB mRNA, IGF-1 mRNA, and IGFBP-3 mRNA in liver tissues (including tumor tissues and adjacent non-tumor tissues) were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Liver Ki67 immunohistochemistry staining was studied. At the same time, 12 patients with cholelithiasis or liver angioma who underwent operation were segregated as normal control.
RESULTS: In HCC patients with cirrhosis, hepatic ALB mRNA, IGF-1 mRNA, and IGFBP-3 mRNA of tumor tissues or adjacent non-tumor tissues were lower than the normal liver tissues, while in tumor tissues, hepatic ALB mRNA and IGFBP-3 mRNA were lower, hepatic IGF-1 mRNA was higher than in adjacent non-tumor tissues. Liver Ki67 labeling index (Ki67 LI) in tumor tissues or adjacent non-tumor tissues were higher than that in the normal liver tissues, while in tumor tissues it was higher than that in adjacent non-tumor tissues.
CONCLUSION: Imbalance of IGF-1 and IGFBP-3 may play a role in hepatocarcinogenesis and tumor development of liver cirrhosis patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015705      PMCID: PMC4615458          DOI: 10.3748/wjg.v11.i27.4272

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.

Authors:  S Rajaram; D J Baylink; S Mohan
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

Review 2.  Insulin-like growth factors; autocrine, paracrine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments.

Authors:  J M Holly; J A Wass
Journal:  J Endocrinol       Date:  1989-09       Impact factor: 4.286

3.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 4.  Insulin-like growth factor II (IGF-II).

Authors:  S D O'Dell; I N Day
Journal:  Int J Biochem Cell Biol       Date:  1998-07       Impact factor: 5.085

5.  In situ hybridization of albumin mRNA in normal liver and liver tumors: identification of hepatocellular origin.

Authors:  K Yamaguchi; M A Nalesnik; B I Carr
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1993

6.  IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells.

Authors:  John F Kuemmerle; Karnam S Murthy; Jennifer G Bowers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-06-03       Impact factor: 4.052

7.  Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma.

Authors:  E J Schoenle; J Zapf; A Prader; T Torresani; E A Werder; M Zachmann
Journal:  J Clin Endocrinol Metab       Date:  1995-02       Impact factor: 5.958

8.  Regulation of insulin-like growth factor I gene expression by growth hormone.

Authors:  L S Mathews; G Norstedt; R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Insulin-like growth factor binding protein-3 in patients with liver cirrhosis.

Authors:  K Sídlová; M Pechová; K Kotaska; R Průsa
Journal:  Physiol Res       Date:  2002       Impact factor: 1.881

10.  Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers.

Authors:  S Tanaka; K Takenaka; T Matsumata; R Mori; K Sugimachi
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

View more
  19 in total

1.  Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.

Authors:  Wen Hui Lin; Janet L Martin; Deborah J Marsh; Michelle M Jack; Robert C Baxter
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

Review 2.  Starvation, detoxification, and multidrug resistance in cancer therapy.

Authors:  Changhan Lee; Lizzia Raffaghello; Valter D Longo
Journal:  Drug Resist Updat       Date:  2012-03-04       Impact factor: 18.500

3.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

4.  I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Authors:  Ahmed O Kaseb; James L Abbruzzese; Jean-Nicolas Vauthey; Thomas A Aloia; Eddie K Abdalla; Manal M Hassan; E Lin; Lianchun Xiao; Adel S El-Deeb; Asif Rashid; Jeffrey S Morris
Journal:  Oncology       Date:  2011-08-03       Impact factor: 2.935

5.  Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization.

Authors:  Sheng Liu; Yanhua Liu; Xuewen Jiang
Journal:  Exp Ther Med       Date:  2015-12-16       Impact factor: 2.447

6.  Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.

Authors:  Danira Ashraf Habashy; Hend Mohamed El Tayebi; Injie Omar Fawzy; Karim Adel Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  World J Hepatol       Date:  2016-08-18

7.  Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old.

Authors:  Dilek Colak; Muhammad A Chishti; Al-Bandary Al-Bakheet; Ahmed Al-Qahtani; Mohamed M Shoukri; Malcolm H Goyns; Pinar T Ozand; John Quackenbush; Ben H Park; Namik Kaya
Journal:  Mol Cancer       Date:  2010-06-12       Impact factor: 27.401

8.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

9.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

10.  Insulin-like growth factor binding protein-3 is required for the regulation of rat oval cell proliferation and differentiation in the 2AAF/PHX model.

Authors:  Nicole C Steiger-Luther; Houda Darwiche; Seh-Hoon Oh; Jennifer M Williams; Bryon E Petersen
Journal:  Hepat Med       Date:  2010-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.